These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1044 related items for PubMed ID: 16813873

  • 1. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni G.
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P, European Organization for the Research and Treatment of Cancer-Genito-Urinary Group.
    J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
    [Abstract] [Full Text] [Related]

  • 4. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study.
    Pan CW, Shen ZJ, Ding GQ.
    J Urol; 2008 Apr; 179(4):1307-11; discussion 1311-2. PubMed ID: 18289576
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results.
    Losa A, Hurle R, Lembo A.
    J Urol; 2000 Jan; 163(1):68-71; discussion 71-2. PubMed ID: 10604316
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance.
    Griffiths TR, Charlton M, Neal DE, Powell PH.
    J Urol; 2002 Jun; 167(6):2408-12. PubMed ID: 11992047
    [Abstract] [Full Text] [Related]

  • 11. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
    Iturralde Codina A, Beyríe Tamayo W, Gozá León F, Muñoz YI.
    Arch Esp Urol; 2004 Jun; 57(6):606-18. PubMed ID: 15382436
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.
    Guevara A, Salomon L, Allory Y, Ploussard G, de la Taille A, Paul A, Yiou R, Hoznek A, Dahan M, Abbou CC, Vordos D.
    J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
    Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP.
    J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer.
    Bisiaux A, Thiounn N, Timsit MO, Eladaoui A, Chang HH, Mapes J, Mogenet A, Bresson JL, Prié D, Béchet S, Baron C, Sadorge C, Thomas S, Albert EB, Albert PS, Albert ML.
    J Urol; 2009 Apr; 181(4):1571-80. PubMed ID: 19230924
    [Abstract] [Full Text] [Related]

  • 19. Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG.
    Mugiya S, Ozono S, Nagata M, Takayama T, Ito T, Maruyama S, Hadano S, Nagae H.
    Jpn J Clin Oncol; 2005 Jul; 35(7):395-9. PubMed ID: 15976065
    [Abstract] [Full Text] [Related]

  • 20. [Intravesical Bacillus Calmette-Guerin (BCG: Tokyo 172 strain) instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG].
    Mugiya S, Nagata M, Takayama T, Ozono S, Ito T, Maruyama S, Hadano S, Nagae H.
    Hinyokika Kiyo; 2004 Jul; 50(7):469-73. PubMed ID: 15334890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.